Temasek-backed Firms Buy Stake In VIVA Biotech Unit Ahead Of Listing
(Reuters) – Entities backed by Singapore’s Temasek and Chinese investment firm HighLight Capital agreed to a deal worth 1.06 billion yuan ($148.7 million) for stakes in a unit of VIVA Biotech Holdings, the pharmaceutical service company said late on Sunday. The deal, which will dilute VIVA Biotech’s stake in VIVA Shanghai to about 75.79% from…